Relapsing remitting multiple sclerosis Trials in London, United Kingdom
Conditions / Relapsing remitting multiple sclerosis / London, United Kingdom
Relapsing remitting multiple sclerosis has been the subject of sustained clinical investigation across multiple research sites.
23 total trials for this combination
Showing top 10 of 23 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT00641537 | CLARITY Extension Study | COMPLETED | PHASE3 |
| NCT00297232 | Natalizumab (Tysabri) Re-Initiation of Dosing | TERMINATED | PHASE3 |
| NCT00078338 | Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis | COMPLETED | PHASE4 |
| NCT00835770 | BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) | COMPLETED | PHASE3 |
| NCT02255656 | Phase IIIB-IV Long-Term Follow-up Study for Patients Who Participated in CAMMS03409 | COMPLETED | PHASE4 |
| NCT05123703 | A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01797965 | Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301 (NCT01064401) to Evaluate the Safety and Efficacy of BIIB019 | TERMINATED | PHASE3 |
| NCT02283853 | Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS) | COMPLETED | PHASE3 |
| NCT00420212 | Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |
| NCT01064401 | Efficacy and Safety of BIIB019 (Daclizumab High Yield Process) Versus Interferon β 1a in Participants With Relapsing-Remitting Multiple Sclerosis | COMPLETED | PHASE3 |